報價延遲最少15分鐘:2024/12/25 00:37 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.42/-4.00
|
|
企業價值
6.98B
|
| 資產負債 |
|
每股賬面淨值
-6.51
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.30M
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 00:37 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |